ABOUT US

Innately Curing Cancer

LIfT Biosciences is a biotech bringing to market a first in class allogeneic innate cell therapy called Neutrophil based Leukocyte Infusion Therapy (N-LIfT). N-LIfT is the world's first neutrophil-based cancer therapeutic product that has the game-changing potential to destroy all solid tumours irrespective of mutation or strain. N-LIfT uses a special type of N1a neutrophil with special cancer killing and immune recruitment capabilities, whilst additionally maintaining minimal damage to healthy cells. 

 

Our vision is to develop the world’s first cell bank of mass produced ‘cancer killing neutrophils’ to deliver a portfolio of immuno-oncology cell therapies for delivering complete remission in all solid tumours. Our planned Series A in 2021 will fund our manufacture scale-up and phase I/II orphan PoC trial is in some of the most challenging solid tumours e.g. Pancreatic (PDAC), Liver (HCC) and Lung (NSCLC).

 

LIfT BioSciences’ N-LifT therapy platform is an off-the-shelf allogeneic patented product that we mass-produce from exceptional stem cells from donors with exceptional immunity. The neutrophils obtained from these donors have L-selectin binding that allows them to move through a concentration gradient of chemotactic ligands towards the tumour cell and selectively bind.

LIfT BioSciences are the industry leaders in neutrophil ATMPs (currently only), the team is made-up from a combination of experienced industry executives and world-class scientists and experts, such as Professor Zheng Cui of Wake Forrest University. LIfT has already proven to be 100% curative in mice and with promising human data in an FDA approved safety trial showing up to 80% tumour necrosis in a mix of late-stage carcinoma patients even at low dose.

We are currently completing pre-clinical work before running our first-in-human clinical trial. The aim is to demonstrate remission in high unmet need solid tumours by 2022, including pancreatic cancer. 

The video below shows LIfT in action killing Cervical Cancer Cells:

Stem Cells

Stem Cells

Scientist in the Lab

Scientist in the Lab

Pipetting Samples

Pipetting Samples

Neutrophil in action

Neutrophil in action

Neutrophil

Neutrophil

Edited Image 2016-07-04 13-47-24

Edited Image 2016-07-04 13-47-24

 

Disclaimer: The information, documents and graphic depictions (the "Information") published on this Web site are the property of LIfT BioSciences Ltd. LIfT BioSciences assumes no responsibility for errors or omissions in the Information on this website. In no event shall LIfT BioSciences be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of this Web site or the Information. LIfT BioSciences reserves the right to make additions, deletions, or modification to the Information on the Web site at any time without prior notice.

  • CEO's Linked-in
  • CEO's Twitter
  • LIfTBio on Facebook

©2016 LIfT BioSciences Ltd

Stem Cells